Literature DB >> 31332347

HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity.

Shiying Wu1, Qian Zhang1,2, Fei Zhang1, Fansen Meng1,2, Shengduo Liu1, Ruyuan Zhou1, Qingzhe Wu1, Xinran Li1, Li Shen1, Jun Huang1, Jun Qin3, Songying Ouyang4, Zongping Xia5, Hai Song1, Xin-Hua Feng1,6, Jian Zou7, Pinglong Xu8,9.   

Abstract

Sensing cytosolic DNA through the cGAS-STING pathway constitutes a widespread innate immune mechanism to monitor cellular damage and microbial invasion. Evading this surveillance is crucial in tumorigenesis, but the process remains largely unexplored. Here, we show that the receptor tyrosine kinase HER2 (also known as ErbB-2 or Neu) potently inhibits cGAS-STING signalling and prevents cancer cells from producing cytokines, entering senescence and undergoing apoptosis. HER2, but not EGFR, associates strongly with STING and recruits AKT1 (also known as PKB) to directly phosphorylate TBK1, which prevents the TBK1-STING association and TBK1 K63-linked ubiquitination, thus attenuating STING signalling. Unexpectedly, we observed that DNA sensing robustly activates the HER2-AKT1 axis, resulting in negative feedback. Accordingly, genetic or pharmacological targeting of the HER2-AKT1 cascade augments damage-induced cellular senescence and apoptosis, and enhances STING-mediated antiviral and antitumour immunity. Thus, our findings reveal a critical function of the oncogenic pathway in innate immune regulation and unexpectedly connect HER2-AKT1 signalling to the surveillance of cellular damage and antitumour immunity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31332347     DOI: 10.1038/s41556-019-0352-z

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  49 in total

Review 1.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 2.  Antitumour immunity regulated by aberrant ERBB family signalling.

Authors:  Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

3.  Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.

Authors:  Mengli Xu; Xiangrui Meng; Yao Lu; Feng Wang
Journal:  J Gastrointest Oncol       Date:  2022-04

4.  Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.

Authors:  Piaopiao Xu; Xiangling Chen; Yongping Xu; Li Fu; Yun Li; Haoyu Fu; Qing Yao; Haitian Quan; Liguang Lou
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 5.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.

Authors:  Giulia Petroni; Aitziber Buqué; Lisa M Coussens; Lorenzo Galluzzi
Journal:  Nat Rev Drug Discov       Date:  2022-03-15       Impact factor: 84.694

6.  EGFR-mediated tyrosine phosphorylation of STING determines its trafficking route and cellular innate immunity functions.

Authors:  Chenyao Wang; Xin Wang; Manoj Veleeparambil; Patricia M Kessler; Belinda Willard; Saurabh Chattopadhyay; Ganes C Sen
Journal:  EMBO J       Date:  2020-09-14       Impact factor: 11.598

Review 7.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Authors:  Martin McLaughlin; Emmanuel C Patin; Malin Pedersen; Anna Wilkins; Magnus T Dillon; Alan A Melcher; Kevin J Harrington
Journal:  Nat Rev Cancer       Date:  2020-03-11       Impact factor: 60.716

8.  A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo.

Authors:  Yan Yan; Xiao Cheng; Lin Li; Rumeng Zhang; Yong Zhu; Zhengsheng Wu; Keshuo Ding
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

9.  Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells.

Authors:  Junji Xing; Ao Zhang; Yong Du; Mingli Fang; Laurie J Minze; Yong-Jun Liu; Xian Chang Li; Zhiqiang Zhang
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

10.  Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.

Authors:  Wei-Jiang Zhao; Guan-Yong Ou; Wen-Wen Lin
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.